Compare Cassava Sciences Inc (FLNA) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Wheaton Precious Metals Corp — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Wheaton Precious Metals Corp trades at $138.43 (market cap $61.17B). The key difference: Wheaton Precious Metals Corp is far larger — about 1552.5× Cassava Sciences Inc's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Wheaton Precious Metals Corp for 66 Days on average.
| FLNA | WPM | |
|---|---|---|
Market Cap | $39.40M | $61.17B |
Volume | 759,018 | 1,092,361 |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $165.72 |
52-Week Low | $0.68 | $94.37 |
Typical Hold Time | 37 Days | 66 Days |
Enterprise Value | -$43.28M | $63.05B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
Wheaton Precious Metals (WPM) trades at $133.69, down 2.88% on the day, amid a bearish technical signal. The company reported record H1 2026 revenues and beat EPS estimates for three consecutive quarters, with strong profitability margins (gross margin 75.25%, net margin 64.66%). Recent news highlights a growth strategy targeting 1.2 million ounces of production by 2030 through an expanded deal pipeline, supported by a fully funded capital plan.
The outlook remains positive given robust earnings momentum and analyst consensus (80% buy ratings, $164.80 price target). Key risks include execution of growth targets and sensitivity to gold/silver prices. The stock offers exposure to precious metals with high margins but trades at premium valuations (P/E 29.94, P/S 19.36), requiring confidence in delivery of projected growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
